3-(4-chlorophenyl)-N-ethylpropanamide | 1314661-21-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-chlorophenyl)-N-ethylpropanamide
• CAS: 1314661-21-6
• 化学式: C₁₁H₁₄ClNO
• mdl: MFCD24389338
• 分子量: 211.691
• InChiKey: QUBMJLSIOMGBSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-N-ethylpropanamide 在 劳森试剂 、 mercury(II) diacetate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 5,5-dimethyl-1,3-cyclohexadiene 、 甲苯 为溶剂， 反应 5.0h， 生成 4-((5-(4-chlorophenethyl)-4-ethyl-4H-1,2,4-triazol-3-yl)methyl)-6-(trifluoromethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
  参考文献：
  名称：

  Discovery of non-glucoside SGLT2 inhibitors

  摘要：

  A series of benzothiazinone and benzooxazinone derivatives were discovered as SGLT2 inhibitors. The optimization led to the discovery of compounds 31 and 32, which exhibited similar potency and better SGLT1 selectivity compared to dapagliflozin. These compounds may provide novel promising scaffolds, which are different from phlorizin-based SGLT2 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.056
• 作为产物：
  描述：

  3-(4-氯苯基)丙酸 、 乙胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-(4-chlorophenyl)-N-ethylpropanamide
  参考文献：
  名称：

  Discovery of non-glucoside SGLT2 inhibitors

  摘要：

  A series of benzothiazinone and benzooxazinone derivatives were discovered as SGLT2 inhibitors. The optimization led to the discovery of compounds 31 and 32, which exhibited similar potency and better SGLT1 selectivity compared to dapagliflozin. These compounds may provide novel promising scaffolds, which are different from phlorizin-based SGLT2 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.056

文献信息

• 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1556361A2

  公开（公告）日：2005-07-27
• [EN] MELANOCORTIN RECEPTOR LIGANDS<br/>[FR] LIGANDS DES RECEPTEURS DE LA MELANOCORTINE
  申请人：PROCTER & GAMBLE

  公开号：WO2004037797A2

  公开（公告）日：2004-05-06

  The present invention relates to compounds which comprise a nitrogen-containing ring scaffold substituted by an R1 alkyl units selected from the group consisting of C1-C12 linear or branched alkyl, C3-C8 cyclic alkyl, C2-C12 linear or branched alkenyl, or haloalkyl, for example, the 2-keto-3-alkylpiperazines having the formula (I): wherein R is selected from the group consisting of phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, and 4-chlorophenyl; R1 is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, benzyl, allyl, 1-methylallyl, 2-methylallyl, but-2-enyl, and propargyll; R7a is selected from the group consisting of hydrogen, -CO2H, -CONH2, -CONHCH3, and -CON(CH3)2; R8 is benzyl, substituted benzyl, or naphthalen-2-ylmethyl..
• Discovery of non-glucoside SGLT2 inhibitors
  作者：An-Rong Li、Jian Zhang、Joanne Greenberg、TaeWeon Lee、Jiwen Liu

  DOI：10.1016/j.bmcl.2011.02.056

  日期：2011.4

  A series of benzothiazinone and benzooxazinone derivatives were discovered as SGLT2 inhibitors. The optimization led to the discovery of compounds 31 and 32, which exhibited similar potency and better SGLT1 selectivity compared to dapagliflozin. These compounds may provide novel promising scaffolds, which are different from phlorizin-based SGLT2 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.